Quarterly Result6 Aug 2025, 08:48 am
Wanbury Ltd Q1FY26 PAT Surges to ₹13.5 Crore vs ₹1.0 Crore YoY
AI Summary
Wanbury Ltd has announced its Q1FY26 un-audited financial results. The company's revenue from operations stood at ₹163.2 crore, up by 24% YoY. EBITDA (including other income) stood at ₹24.8 crore, a growth of 108%. PAT for the quarter was ₹13.5 crore, a surge of 1198% YoY. The company has also launched its innovative liposomal iron supplement, Wanbury C RED, and received GMP certification from Brazil's health authority ANVISA for its API manufacturing sites at Patalganga and Tanuku.
Key Highlights
- Q1FY26 revenue from operations stood at ₹163.2 crore, a YoY growth of 24%
- EBITDA (including other income) stood at ₹24.8 crore, a growth of 108%
- PAT for the quarter was ₹13.5 crore, a surge of 1198% YoY
- Wanbury Ltd has successfully launched its innovative liposomal iron supplement, Wanbury C RED
- Wanbury Limited’s API manufacturing sites at Patalganga and Tanuku have both successfully received Good Manufacturing Practices (GMP) certification from Brazil's health authority ANVISA